UBX

Unity Biotechnology, Inc. [UBX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

UBX Stock Summary

In the News

04:45 27 Sep 2023 UBX

Unity (UNX) Down on Disappointing Results From Wet AMD Study

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

12:00 27 Sep 2023 UBX

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?

Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).

12:45 27 Sep 2023 UBX

Unity Biotechnology (UBX) Stock Pops on Positive Study Data

Unity Biotechnology (NASDAQ: UBX ) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. UBX1325 is the company's treatment in development to treat patients dealing with diabetic macular edema (DME).

08:15 27 Sep 2023 UBX

Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results

A small cap biotech targeting diseases of ageing, with a lead compound focusing on ophthalmology that recently reported positive trial results. Not overly reliant on debt and has reported some revenues with relatively stable overall financials.

01:32 27 Sep 2023 UBX

All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy

UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

07:00 27 Sep 2023 UBX

The Three Best Anti-Aging Stocks to Buy in September

Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth companies.

08:00 27 Sep 2023 UBX

UNITY Biotechnology to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September.

11:17 27 Sep 2023 UBX

Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now

UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

06:00 27 Sep 2023 UBX

Hot Penny Stocks to Add to Your Watchlist Right Now

Here's what you need to know about trading penny stocks on August 15th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:05 27 Sep 2023 UBX

Why Is Unity Biotechnology (UBX) Stock Up 71% Today?

Source: everything possible / Shutterstock.com Unity Biotechnology (NASDAQ: UBX ) stock is surging higher on Friday following the release of its earnings report for the second quarter of 2022. That report starts with the company's current cash position sitting at $64.5 million.

UBX Financial details

Company Rating
Buy
Market Cap
36.07M
Income
-52.33M
Revenue
-236K
Book val./share
3.42
Cash/share
4.79
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
06 Nov 2023
P/E
-0.66
Forward P/E
-
PEG
0.11
P/S
-147.25
P/B
0.69
P/C
0.5
P/FCF
-0.8
Quick Ratio
3.19
Current Ratio
3.28
Debt / Equity
0.87
LT Debt / Equity
0.59
-
-
EPS (TTM)
-4.08
EPS next Y
-
EPS next Q
-
EPS this Y
-43.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
1.19%
-
-
-
-
SMA20
-33.33%
SMA50
-33.33%
SMA100
-
Inst Own
1.11%
Inst Trans
0%
ROA
-52%
ROE
-83%
ROC
-0.63%
Gross Margin
100%
Oper. Margin
21043%
Profit Margin
22173%
Payout
-
Shs Outstand
14.6M
Shs Float
13.36M
-
-
-
-
Target Price
80
52W Range
1.461-5.72
52W High
-51.68%
52W Low
+141.59%
RSI
44
Rel Volume
0.4
Avg Volume
108.61K
Volume
43.48K
Perf Week
-3.36%
Perf Month
-5.26%
Perf Quarter
61.06%
Perf Half Y
23.89%
-
-
-
-
Beta
0.612033
-
-
Volatility
0.07%, 0.09%
Prev Close
1.51%
Price
2.4159
Change
0.24%

UBX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0000.860.02
Net income per share
-27.02-17.16-18.06-10.76-6.08
Operating cash flow per share
-20.03-16.6-15.4-8.07-5.37
Free cash flow per share
-20.48-16.96-15.53-8.11-5.38
Cash per share
60.5429.2219.2115.789.98
Book value per share
56.8427.6716.2910.677.04
Tangible book value per share
56.8427.6716.2910.677.04
Share holders equity per share
56.8427.6716.2910.677.04
Interest debt per share
1.17012.749.815.36
Market cap
459.67M314.53M266.53M81.49M26.01M
Enterprise value
444.39M277.06M307.7M100.14M60.64M
P/E ratio
-6.02-4.2-2.9-1.36-0.45
Price to sales ratio
00017.03110.23
POCF ratio
-8.12-4.34-3.4-1.81-0.51
PFCF ratio
-7.94-4.25-3.37-1.8-0.51
P/B Ratio
2.862.613.221.370.39
PTB ratio
2.862.613.221.370.39
EV to sales
00020.93256.94
Enterprise value over EBITDA
-6.31-3-3.42-1.74-1.08
EV to operating cash flow
-7.85-3.83-3.93-2.22-1.19
EV to free cash flow
-7.68-3.74-3.9-2.21-1.19
Earnings yield
-0.17-0.24-0.34-0.74-2.22
Free cash flow yield
-0.13-0.24-0.3-0.56-1.97
Debt to equity
000.770.870.71
Debt to assets
000.410.410.38
Net debt to EBITDA
0.220.41-0.46-0.32-0.61
Current ratio
10.437.526.975.454.92
Interest coverage
-23.990-72.7-17.84-16.18
Income quality
0.740.880.830.740.85
Dividend Yield
0.130000
Payout ratio
-0.80000
Sales general and administrative to revenue
0004.8288.77
Research and developement to revenue
0008.03156.18
Intangibles to total assets
00000
Capex to operating cash flow
0.020.020.0100
Capex to revenue
000-0.04-0.41
Capex to depreciation
-0.58-0.6-0.19-0.07-0.04
Stock based compensation to revenue
0002.4139.74
Graham number
185.91103.3781.3750.8231.04
ROIC
-0.51-0.68-0.51-0.4-0.39
Return on tangible assets
-0.42-0.5-0.59-0.48-0.46
Graham Net
53.2222.234.774.113.93
Working capital
156.38M112.27M86.4M73.89M76.92M
Tangible asset value
160.69M120.71M82.88M59.57M66.85M
Net current asset value
152.28M98.97M27.43M25.36M39.03M
Invested capital
000.770.870.71
Average receivables
691K0000
Average payables
3.61M5.02M3.87M2.27M1.89M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.48-0.62-1.11-1.01-0.86
Capex per share
-0.45-0.36-0.13-0.03-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
0.030-0.0200
Net income per share
-2.02-1.42-0.97-0.84-0.85
Operating cash flow per share
-2.14-1.08-0.73-0.79-0.77
Free cash flow per share
-2.16-1.08-0.74-0.79-0.77
Cash per share
9.329.826.75.834.79
Book value per share
5.777.84.734.13.42
Tangible book value per share
5.777.84.734.13.42
Share holders equity per share
5.777.84.734.13.42
Interest debt per share
7.114.833.423.343.05
Market cap
39.06M39.78M38.75M23.33M36.79M
Enterprise value
67.94M65.04M73.37M47.19M60.75M
P/E ratio
-0.7-0.7-0.7-0.48-0.75
Price to sales ratio
165.490-164.1700
POCF ratio
-2.63-3.66-3.74-2.06-3.32
PFCF ratio
-2.61-3.65-3.72-2.06-3.32
P/B Ratio
0.980.510.580.40.74
PTB ratio
0.980.510.580.40.74
EV to sales
287.90-310.8800
Enterprise value over EBITDA
-5.84-5.28-5.57-4.78-5.57
EV to operating cash flow
-4.58-5.99-7.08-4.17-5.48
EV to free cash flow
-4.53-5.96-7.05-4.17-5.48
Earnings yield
-0.36-0.36-0.36-0.52-0.33
Free cash flow yield
-0.38-0.27-0.27-0.49-0.3
Debt to equity
1.210.610.710.80.87
Debt to assets
0.50.350.380.410.43
Net debt to EBITDA
-2.48-2.05-2.63-2.42-2.2
Current ratio
4.136.124.9243.28
Interest coverage
-13.71-15.16-14.06-10.63-12.22
Income quality
1.130.790.731.040.91
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
20.940-22.3700
Research and developement to revenue
320-36.5900
Intangibles to total assets
00000
Capex to operating cash flow
0.010000
Capex to revenue
-0.6400.1600
Capex to depreciation
-0.25-0.09-0.0900
Stock based compensation to revenue
9.530-9.5700
Graham number
16.2115.7810.178.828.07
ROIC
-0.11-0.09-0.1-0.09-0.11
Return on tangible assets
-0.14-0.1-0.11-0.11-0.12
Graham Net
0.994.082.641.941.36
Working capital
51.4M85.95M76.92M64.8M50.74M
Tangible asset value
39.93M78.57M66.85M58.63M49.41M
Net current asset value
10.16M44.9M39.03M30.75M21.37M
Invested capital
1.210.610.710.80.87
Average receivables
0000871.5K
Average payables
2.38M1.94M2.12M1.63M1.46M
Average inventory
0000880.5K
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.35-0.18-0.21-0.21-0.25
Capex per share
-0.020000

UBX Frequently Asked Questions

What is Unity Biotechnology, Inc. stock symbol ?

Unity Biotechnology, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol UBX

What is Unity Biotechnology, Inc. stock quote today ?

Unity Biotechnology, Inc. stock price is $2.4159 today.

Is Unity Biotechnology, Inc. stock public?

Yes, Unity Biotechnology, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Same Price Range
Similar Market Cap